All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit the International Myeloma Foundation or HealthTree for Multiple Myeloma.
An expert panel hosted by
Sequencing immune-based therapies in B-cell malignancies
with Ulric Jäger, Sagar Lonial, and Krina Patel
Saturday, June 15 | 18:00-19:30 CEST
Register nowThis independent education activity is sponsored by Bristol Myers Squibb. All content is developed independently by the faculty. Funders are allowed no direct influence on the content of this activity.
The Multiple Myeloma Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the Multiple Myeloma Hub cannot guarantee the accuracy of translated content. The Multiple Myeloma Hub and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
During the 65th American Society of Hematology (ASH) Annual Meeting and Exposition, the Multiple Myeloma Hub spoke to Danai Dima, Taussig Cancer Institute, Cleveland, US. We asked, What are the real-world outcomes following treatment with teclistamab in relapsed/refractory multiple myeloma?
What are the real-world outcomes following treatment with teclistamab in RRMM?
Dima provides a summary of data from the MajesTEC-1 trial (NCT03145181), which led to the regulatory approval of teclistamab. She highlights variation in patient demographics between the clinical trial and real-world settings, emphasizing outcomes for those who were ineligible for the trial. She then evaluates data from patients with high-risk features, extramedullary disease, and prior B-cell maturation antigen-targeted therapies. Dima concludes with a discussion on how treatment with teclistamab may be incorporated into the community care setting.
Subscribe to get the best content related to multiple myeloma delivered to your inbox